Table 1.
Clinical, laboratory and imaging findings of children with SARS CoV-2.
| Patient 1 | Patient 2 | ||
|---|---|---|---|
| Age (years) | 10 | 11 | |
| Sex | Male | Female | |
| Initial central nervous system manifestations | Personality changes Hallucinations |
Personality changes | |
| Respiratory symptoms | Dyspnea, tachypnea | Dyspnea, tachypnea, subcostal retractions | |
| Blood pressure (mm HG) | 99/62 | 91/45 | |
| Pulse rate (per min) | 136 | 140 | |
| SaO2 | 98 | 98 | |
| Laboratory findings | White blood cell (per μL) | 8990 | 6920 |
| Platelet (per μL) | 124,000 | 113,000 | |
| CRP (mg/L) | 392 | 456 | |
| Procalcitonin (ng/mL) (N: 0–0.5) |
114 | 32 | |
| IL-6 (pg/mL) (N: 0–7) |
66 | 898 | |
| Ferritin (µg/L) (N: 24–336) |
341 | 533 | |
| Troponin I (ng/ml) (N: 0–17.5) |
321 | 182 | |
| Pro-BNP (ng/L) (N: 0–133) |
13,800 | 35,000 | |
| Fibrinogen (mg/dL) (N: 200–400) |
615 | 794 | |
| D-dimer (µg FEU/mL) (N: 0–0.5) |
1.19 | 1.7 | |
| Albumin (g/L) | 33 | 21 | |
| Natrium (mmol/L) | 131 | 132 | |
| AST (U/L) | 34 | 37 | |
| ALT (U/L) | 24 | 37 | |
| CSF | Glucose (mg/dL) | 92 | N/A |
| Protein (mg/dL) | 20 | N/A | |
| Cell count (/mm3) | none | N/A | |
| Oligoclonal band | negative | N/A | |
| Chest X-ray | Prominent bronchovascular markings | Prominent bronchovascular markings | |
| EEG | Diffuse slowing | Diffuse slowing | |
| Brain MRI | on admission | Hyperintensity in the splenium of the corpus callosum | Hyperintensity in the splenium of the corpus callosum |
| on day 7 | normal | normal | |
| Immune treatment | IVIG (2 g/kg, 1 dose) MP (1 mg/kg/day) |
IVIG (2 g/kg, 1 dose) MP (20 mg/kg/day, 2 days)MP (1 mg/kg/day) |
Abbreviations: AST = Aspartate aminotransferase, ALT = Alanine aminotransferase, CSF = Cerebrospinal fluid, CRP = C-reactive protein, EEG = Electroencephalography, IL-6 = Interleukin 6, IVIG = Intravenous immunoglobulin, MP = Methylprednisolone, MRI = Magnetic resonance imaging, N/A = not available, pro-BNP = Pro–B-type natriuretic peptide.